Nuformix PLC (NFX)

ORD 0.05P

Sell: 0.23p|Buy: 0.27p|Change: 0.02 (-7.20%)

Open

0.25p

Previous close

0.25p

Trade high

0.27p

Volume

7,662,952

Year high

0.555p

Year low

0.0125p

Dividend yield

–

Market capitalisation

£4.89 mn

P/E ratio

–

ISIN

GB00BYW79Y38

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 16/12/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Nuformix PLC	- 7.41
More...

Company profile

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
18/12/2025	03:56:13	0.2448	500,000	1,224.00
18/12/2025	03:46:04	0.2448	811,307	1,986.08
18/12/2025	03:41:58	0.25	5,791	14.48
18/12/2025	02:47:32	0.232	131,875	305.95
18/12/2025	01:49:01	0.231	54,736	126.44

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.